![[logo] US EPA](http://www.epa.gov/epafiles/images/logo_epaseal.gif){kind=logo}
Effluent Guidelines
Pharmaceutical Manufacturing
Economic Analysis for Final Effluent Limitations Guidelines and Standards
You will need Adobe Reader to view some of the files on this page. See EPA's PDF page to learn more.
This document can be downloaded in its entirety (PDF) (993 K, 295 pages) or by individual sections as listed below.
- Table of Contents (PDF) 53 K, 13 pages)
- Section 1: Executive Summary (PDF) (101 K, 23 pages)
- An introduction to the Economic Assessment, including a general outline describing the scope of each analysis.
- Section 2: Data Sources (PDF) (24 K, 5 pages)
- A summary of the primary data sources used for the Economic Assessment
- Section 3: Profile of the Pharmaceutical Industry (PDF) (342 K, 85 pages)
- This section is organized into three subsections that address the principal determinants of supply and demand for U.S. Pharmaceuticals and present key industry statistics.
- Section 4: Economic Impact Analysis Methodology Overview and Compliance Cost Analysis (PDF) (76 K, 14 pages)
- The overview of the EA methodology and describes the principal economic and financial models used.
- Section 5: Analysis of Facility-Level Impacts (PDF) (45 K, 12 pages)
- The facility-level economic impact methodology and reports on the results of the facility economic impact analysis.
- Section 6: Analysis of Firm-Level Impacts (PDF) (85 K, 16 pages)
- The effects of regulatory compliance on owner companies in the firm-level analysis.
- Section 7: National and Regional Employment Impacts and Total Output Losses (PDF) (111 K,26 pages)
- Impacts on national-level and industry-level output and employment from the Final Pharmaceutical Industry Effluent Guidelines and MACT standards rule.
- Section 8: Other Secondary Impacts (PDF) (85 K, 21 pages)
- Five separate types of impacts: impacts on trade, impacts on inflation, impacts on POTWs through reductions in revenues related to reductions in loadings, impacts on distributional equity through potential product price increases, and impacts on environmental justice.
- Section 9: Final Regulatory Flexibility Analysis (PDF) (28 K,7 pages)
- Examines the projected effects of the costs from incremental pollution control on small entities as required by the Regulatory Flexibility Act as amended by the Small Business Regulatory Enforcement Fairness Act of 1996.
- Section 10: Costs and Benefits of the Pharmaceutical Industry Guidelines (PDF) (196 K, 49 pages)
- Costs and benefits of the Final Pharmaceutical Industry Effluent Guidelines and the MACT standards rule.
- Appendices (PDF) (131 K, 24 pages)